title: Nosocomial cerebral aspergillosis: a report of 3 cases.
abstract: Cerebral aspergillosis carries a mortality rate close to 100%, especially in immunocompromised patients. We describe 3 patients who contracted cerebral aspergillosis after neurosurgery, 2 of whom survived after exhaustive surgical treatment and medical treatment with high doses of amphotericin B (once liposomal), 5-fluorocytosine and itraconazole. We review the few non-fatal cases of cerebral aspergillosis reported. We consider that surgical excision must be complete and repeated if necessary, always in combination with medical treatment.
authors.affiliation: Clinique de Réanimation des Maladies Infectieuses, Hôpital Bichat-Claude Bernard, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Darras-Joly
authors.forename: B
authors.initials: B
authors.lastname: Veber
authors.forename: J P
authors.initials: JP
authors.lastname: Bedos
authors.forename: B
authors.initials: B
authors.lastname: Gachot
authors.forename: B
authors.initials: B
authors.lastname: Regnier
authors.forename: M
authors.initials: M
authors.lastname: Wolff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D001921:Brain / Q000382:microbiology*; D003428:Cross Infection / Q000175:diagnosis* / Q000188:drug therapy*; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008081:Liposomes; D008297:Male; D009493:Neurosurgery
chemical_list: D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D017964:Itraconazole; D000666:Amphotericin B; D005437:Flucytosine